Research groups
Patrick Julier
OCTRU Head of Programming
I have over 25 years’ experience in the IT industry, working in manufacturing, finance, telecommunications and the public sector before working in Clinical Trials when I joined the Oncology Clinical Trials Office (OCTO) in 2004.
I am OCTRU's Head of Programming and lead a team of 5 programmers/database officers. I joined OCTRU in October 2013 when we had no IT systems to speak of. Since then we have developed 5 systems and installed and support 4 off-the-shelf systems.
We look forward to taking these systems forward and to continue providing a responsive and professional service to all the Clinical Trials Units within the OCTRU family.
Recent publications
-
Hormone replacement therapy (conjugated oestrogens plus bazedoxifene) for post-menopausal women with symptomatic hand osteoarthritis: primary report from the HOPE-e randomised, placebo-controlled, feasibility study.
Journal article
Williams JAE. et al, (2022), Lancet rheumatol, 4, e725 - e737
-
Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial.
Journal article
Abhishek A. et al, (2022), Lancet respir med, 10, 840 - 850
-
Two-week interruption in methotrexate treatment versus treatment continued as usual and COVID-19 booster immunity in adults with inflammatory conditions (VROOM study): a randomised open label, superiority trial
Journal article
Abhishek A. et al, (2022), The lancet respiratory medicine
-
Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine Response On/Off Methotrexate (VROOM) study).
Journal article
Abhishek A. et al, (2022), Bmj open, 12
-
Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial.
Journal article
Kerr RS. et al, (2016), Lancet oncol, 17, 1543 - 1557